XPO1 (CRM1) inhibition represses STAT3 activation to drive a surviving-dependent oncogenic switch in triple negative breast cancer.

XPO1 (CRM1) inhibition represses STAT3 activation to drive a surviving-dependent oncogenic switch in triple negative breast cancer.

Learn More